Diabetes mellitus with normal renal function is associated with anaemia

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 4, 2014, Pages 291-296

  Grossman, Chagai ^a,c   Dovrish, Zamir ^b   Koren Morag, Nira ^c   Bornstein, Gil ^a,c   Leibowitz, Avshalom ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anaemia; Diabetes mellitus; Haemoglobin; Renal functions

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; HEMOGLOBIN;

ADULT; AGE; ANEMIA; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GASTROINTESTINAL DISEASE; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ELECTRONIC MEDICAL RECORD; HEMATOPOIESIS; ISRAEL; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RENAL INSUFFICIENCY; RISK FACTOR; SEX DIFFERENCE;

AGED; ANEMIA; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ELECTRONIC HEALTH RECORDS; FEMALE; GLOMERULAR FILTRATION RATE; HEMATOPOIESIS; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; ISRAEL; KIDNEY; MALE; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY; RISK FACTORS; SEX FACTORS;

EID: 84897948538     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2491     Document Type: Article

References (37)

1. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26(4): 1164-1169.
2. Thomas MC, Tsalamandris C, Macisaac R, Jerums G. Functional erythropoietin deficiency in patients with type 2 diabetes and anaemia. Diabet Med 2006; 23(5): 502-509.
3. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24(3): 495-499.
4. Craig KJ, Williams JD, Riley SG, et al. Anemia and diabetes in the absence of nephropathy. Diabetes Care 2005; 28(5): 1118-1123.
5. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the kidney early evaluation program. Kidney Int 2005; 67(4): 1483-1488.
6. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005; 165(4): 466-469.
7. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2004; 89(9): 4359-4363.
8. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39(11): 1780-1786.
9. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66(3): 1131-1138.
10. Ueda H, Ishimura E, Shoji T, et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care 2003; 26(5): 1530-1534.
11. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20(1): 1-17.
12. Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus. Clin Pharmacol Ther 2007; 82(3): 275-281.
13. Blum A, Ghaben W, Slonimsky G, Simsolo C. Metformin-induced hemolytic anemia. Isr Med Assoc J 2011; 13(7): 444-445.
14. Hidalgo SF, Prieto de Paula JM, Salado Valdivieso I. Metformin and vitamin B12 deficiency. Med Clin (Barc) 2010; 135(6): 286-287.
15. Inoue A, Babazono T, Iwamoto Y. Effects of the renin-angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease. Am J Hypertens 2008; 21(3): 317-322.
16. Leshem-Rubinow E, Steinvil A, Zeltser D, et al. Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Mayo Clin Proc 2012; 87(12): 1189-1195.
17. Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008; 73(5): 630-636.
18. Deray G, Heurtier A, Grimaldi A, Launay Vacher V, Isnard BC. Anemia and diabetes. Am J Nephrol 2004; 24(5): 522-526.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604-612.
20. Mackerras D, Singh G. The prevalence of anaemia depends on the definition: an example from the aboriginal birth cohort study. Eur J Clin Nutr 2007; 61(1): 135-139.
21. Adetunji OR, Mani H, Olujohungbe A, Abraham KA, Gill GV. 'Microalbuminuric anaemia' - the relationship between haemoglobin levels and albuminuria in diabetes. Diabetes Res Clin Pract 2009; 85: 179-182.
22. Jones SC, Smith D, Nag S, et al. Prevalence and nature of anaemia in a prospective, population-based sample of people with diabetes: Teesside anaemia in diabetes (TAD) study. Diabet Med 2010; 27(6): 655-659.
23. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant 2004; 19(7): 1792-1797.
24. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162(12): 1401-1408.
25. Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 2002; 11(3): 337-341.
26. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int 2001; 59(2): 725-731.
27. Nagy J, Kiss I, Wittmann I. Early anemia in diabetic nephropathy. Orv Hetil 2005; 146(9): 397-401.
28. Eschbach JW, Adamson JW. Modern aspects of the pathophysiology of renal anemia. Contrib Nephrol 1988; 66: 63-70.
29. Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med 2002; 19(1): 65-69.
30. Spallone V, Maiello MR, Kurukulasuriya N, et al. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric type 2 diabetic patients? Diabet Med 2004; 21(11): 1174-1180.
31. Thomas M, Tsalamandris C, MacIsaac R, Jerums G. Anaemia in diabetes: an emerging complication of microvascular disease. Curr Diabetes Rev 2005; 1(1): 107-126.
32. Hammerman-Rozenberg R, Jacobs JM, Azoulay D, Stessman J. Aspirin prophylaxis and the prevalence of anaemia. Age Ageing 2006; 35(5): 514-517.
33. Satoh S, Kaneko T, Seino K, et al. Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients. Nippon Jinzo Gakkai Shi 1995; 37(6): 343-347.
34. Tong PC, Kong AP, So WY, et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes. Diabetes Care 2006; 29(11): 2439-2444.
35. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16(11): 3403-3410.
36. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol 2007; 3(1): 20-30.
37. Thomas MC, Cooper ME, Rossing K, Parving HH. Anaemia in diabetes: is there a rationale to TREAT? Diabetologia 2006; 49(6): 1151-1157.